Consistent with previous studies and the recent approval by the U.S. FDA (Cho et al., 2016; Ossenkoppele et al., 2016; Mattsson et al., 2017), the increased pattern of 18F-T807 tracer was well-documented in our AD patients and has served as an imaging marker for detecting mixed 3R and 4R tau in paired helical filaments structures in AD patients. Here, MAPT is linked to Alzheimer disease.